Malaysian Re targets cancer coverage gap with China Re partnership

The treaty supports access to precision medicine through local insurers and takaful operators.

Malaysian Reinsurance Berhad (Malaysian Re) and China Reinsurance Life Insurance Company Limited (China Re Life) have signed a reinsurance treaty to establish Malaysia's first dedicated framework for advanced cancer treatment coverage. 

The agreement supports coverage for Cancer Precision Medicine (CPM), which includes therapies such as CAR-T cell therapy, targeted therapies, and precision immunotherapy. 

These treatments are typically excluded or strictly limited under conventional health insurance plans. 

The framework also includes an overseas benefit, allowing Malaysian policyholders to access treatment at designated oncology centres in China. 

The initiative addresses a significant healthcare gap in Malaysia, where more than 60 % of cancer patients are diagnosed at late stages. 

Under the treaty, which has been in development since 2025, Malaysian Re will provide local insurers and takaful operators with specialised reinsurance capacity to offer these consumer-ready coverages. 

The healthcare ecosystem underpinning the project was coordinated by reinsurance broker Beacon Global Risk Solutions Limited. It connects primary insurers, direct-to-pharmacy distribution networks, hospitals, and pharmaceutical companies. 

China Re Life enters the partnership with an established CPM model that currently covers more than 330 million policyholders annually in China through partnerships with over 180 insurers and 100 pharmaceutical companies. 

Building on this framework, both companies intend to explore expanding their services into critical illness, longevity, and health management solutions across Southeast Asia. 

They also plan to set up joint technical working groups and exchange programmes to accelerate capability sharing between the two institutions.